UCLA announces research collaboration with Takeda to explore impact of circadian rhythm disruption on type 2 diabetes development

October 9, 2013
2 min read

Millions of individuals worldwide are exposed to shift work and numerous environmental conditions that disturb circadian clock function and disrupt normal circadian rhythms. Environmental conditions associated with disrupted circadian rhythms greatly increase the risk for development of type 2 diabetes and metabolic syndrome and also hinder the treatment and management of hyperglycemia in existing patients with diabetes.

A new collaboration effort between the New Frontier Science Group at Takeda Pharmaceutical Company Limited and Dr. Aleksey Matveyenko at the University of California Los Angeles will undertake studies to better understand how disruption of circadian rhythms globally and at the level of pancreatic beta-cells promotes development of type 2 diabetes and, specifically, loss of pancreatic beta-cell function and mass.  This research will provide an enhanced molecular understanding of the relationship between circadian clock disruption, beta-cell dysfunction and loss, and type 2 diabetes that may lead to the development of innovative circadian medicines. 

Opened in November 2004, the Larry L. Hillblom Islet Research Center at UCLA is the first center dedicated to the study of the islets of Langerhans, which include the insulin-producing cells in the pancreas. An understanding of the causes of islet cell destruction is key to finding a cure for diabetes. The Center's faculty members, recruited from around the world, provide leadership in the worldwide fight against the disease. The Center is made possible through a grant from the Larry Hillblom Foundation, established to support medical research in the state of California.

UCLA ranks among the nation's top five institutions in research funding. Groundbreaking innovation and research at UCLA presently generates more than $1 billion in research funding annually. UCLA currently manages approximately 1,800 active inventions and negotiates more than 500 new material transfer agreements, 60 licenses and 400 industry-sponsored research agreements each year.

Takeda's New Frontier Science (NFS) is a newly created group with the mission of finding, developing and integrating innovative foundational technologies into Takeda's drug discovery and development process. NFS provides resources to external innovators through direct funding, access to pharmaceutical drug discovery development resources and collaboration with Takeda scientists and engineers. NFS engages scientists, inventors, or entrepreneurs in collaborative partnerships to advance today's innovations into tomorrow's medicines.   For more information about Takeda, visit http://www.takeda.com/.

Media Contact:
Enrique Rivero
(310) 794-2273
[email protected]
UCLA Health article

Related Content


Media Contact

Enrique Rivero
(310) 794-2273
[email protected]